ArticleLiver cancer2022

Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy.

Hidekatsu Kuroda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.